
For transgender women with HIV, risk awareness and provider trust shape anal cancer follow-up
Key Takeaways
- Transgender women experience markedly higher anal cancer prevalence, driven by high-risk anal HPV, with HIV acting as a major cofactor that increases HSIL risk independent of viral suppression or ART use.
- Consensus guidance recommends screening transgender women with HIV starting at 35 years and without HIV at 45 years, reflecting incidence >70/100,000 person-years in key HIV-affected populations.
Among 16 Black transgender women, 15 with HIV, risk awareness, comfort, provider trust and support shaped whether they completed HRA, according to a new qualitative study.
For transgender women living with
The study was led by a team of researchers, including senior author Darren Whitfield, Ph.D., an associate professor at the University of Maryland School of Social Work. Whitfield and his team included semi-structured interviews with 16 Black transgender women who had abnormal anal cytology and were referred for high-resolution anoscopy (HRA), which detects and treats high-grade squamous intraepithelial lesions (HSIL), the precursor to anal cancer. Half had completed HRA and half had not. Participants were recruited from a clinic that offers gender-affirming care, and most were 35 or older (81%), stably housed (81%) and living with HIV (94%).
How HIV raises anal cancer risk for transgender women
Transgender women face an anal cancer prevalence 5.5 times higher than cisgender individuals, a gap the researchers linked largely to high rates of anal high-risk of human papillomavirus (HPV). The authors described HIV as the second most important risk factor in this population. HIV potentiates HPV infection and raises the likelihood of HSIL regardless of viral suppression or antiretroviral therapy use.
That overlap matters because HIV is concentrated among transgender women. In CDC’s National HIV Behavioral Surveillance of 1,608 transgender women in seven U.S. cities,
The International Anal Neoplasia Society’s 2024
Follow-through after an abnormal result remains a weak point. In an earlier cohort of 75 transgender women, 49% had abnormal cytology. Of those, 89% were referred to HRA, but only 47% completed it.
“This highlights a potential missed opportunity to prevent anal cancer in this population at elevated risk for cancer,” Whitfield and his team wrote in the study.
How HIV awareness affects HRA decisions
Several participants said knowing their HIV status raised their anal cancer risk factored into their decision. “Being that I’m HIV-positive, that it must be addressed immediately,” said one participant, though she had not completed HRA herself. Still, many could not distinguish anal cytology from HRA or from colonoscopy.
Comfort also played a role. Some participants felt emotionally vulnerable having a clinician collect the anal swab, and most who completed HRA reported discomfort that eased when providers explained each step.
Provider trust in HIV and gender-affirming care
Participants who described positive relationships with clinicians were more willing to follow recommendations. One participant who completed HRA said the specialist her primary care doctor referred her to “made it feel at ease.” Others said they preferred to rely on a physician they already knew, and a lack of affirming communication was cited as a barrier.
Whitfield and his team wrote that raising HRA completion may depend on encouragement from providers who serve and are trusted by transgender women. Prior research cited in the paper found an odds ratio of 241.57 for completing anal cytology among transgender individuals when a provider recommended the test.
Why HPV gets less attention than HIV among transgender women
Participants said anal health is rarely discussed in their community, where HIV has long been the focus. “HIV was the higher thing people was scared to talk about and talk to. It wasn’t about HPV,” said one participant who completed HRA. Others said lacking support kept them away. “If I find out I have something, who do I have to cry to? Nobody,” said one participant who did not complete HRA.
The authors recommended gender-neutral HPV education inclusive of transgender women, consistent use of preferred names and pronouns, opportunities for self-collected anal cytology and integration of social support networks into screening programs. They noted the sample came from a single clinic with an existing research partnership and that all participants had healthcare access.
Asked what would help more transgender women complete HRA, one participant who did not complete the procedure said providers “should say more caring [things]. Be more compassionate about the things that trans women go through.”
Related to this article








